Project Grant R56AI203669
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $765K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $872,596 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on HIV-1 antibody responses in people living with HIV who have tuberculosis and other opportunistic coinfections. The research examines how tuberculosis changes both the HIV-1 immune response and the characteristics of circulating viruses in coinfected individuals. The project...
- The National Institute of Allergy and Infectious Diseases awarded Boston Medical Center Corporation $795,622 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mycobacterium tuberculosis impact on HIV reservoir clearance. The research examines how tuberculosis disease affects HIV-1 latent reservoirs in people living with HIV. The study will recruit 200 people with HIV, half with active tuberculosis disease, and follow them for up to 18 months....
- The National Institute of Allergy and Infectious Diseases awarded Dana-Farber Cancer Institute, Inc. $267,000 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on integrase-targeted activators of cell death in HIV-1-infected cells. The research assesses the developmental potential of integrase-targeting compounds to induce pyroptotic cell death in HIV-infected cells, building on prior work with reverse-transcriptase-targeting...
- Federal Project Grant Award Summary Boston Medical Center Corporation received a $711,993 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 11, 2025, with completion targeted for May 31, 2026. This award funds investigator-initiated biomedical research examining the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 (Human Immunodeficiency Virus) pathogenesis,...
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology (MIT) $553,136 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research visualizing HIV-1 capsid passage through the nuclear pore complex. The funded work addresses how HIV-1 traverses the nuclear pore complex during viral entry into the cell nucleus, a critical stage in the infection process preceding uncoating, reverse transcription, and...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $2.373 million on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms controlling HIV-1 latency and reservoir persistence in primary cells. The research develops and deploys a xenograft-based model system in NSG mice to generate human primary memory CD4+ T-cell populations containing latent HIV-1 proviruses with reporter genes. The work...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $162,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the single-cell epigenetic landscape of the HIV-1 reservoir for effective latency reversal. The research will characterize proviral epigenetics—the regulation of transcription at the chromatin level independent of DNA sequence—to understand how latent HIV is established,...